Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
Abstract The expression of mesothelin correlates with a poor prognosis in patients with breast cancer. Since mesothelin plays a role in cancer metastasis in association with CA125, we herein examined the expression of mesothelin and CA125, and the clinicopathological meaning and prognosis of the co-...
Main Authors: | Takahiro Einama, Yoji Yamagishi, Yasuhiro Takihata, Takafumi Suzuki, Tamio Yamasaki, Yuichi Hirose, Kazuki Kobayashi, Naoto Yonamine, Ibuki Fujinuma, Takazumi Tsunenari, Makiko Koga, Yusuke Ishibashi, Ken Nagata, Takehiro Shiraishi, Akiko Nakazawa, Toshimitsu Iwasaki, Eiji Shinto, Kimi Kato, Kimiya Sato, Hideki Ueno, Yoji Kishi, Hitoshi Tsuda |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-021-00335-3 |
Similar Items
-
Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
by: Xianyu Zhang, et al.
Published: (2022-07-01) -
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
by: Jing Guo, et al.
Published: (2024-04-01) -
The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
by: Yu Yi, et al.
Published: (2011-07-01) -
Clinical Impact of Dual Time Point <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer
by: Takahiro Einama, et al.
Published: (2022-07-01) -
Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study
by: Kazuki Kobayashi, et al.
Published: (2022-09-01)